📈 Live Market Tracking
Every NSE and BSE corporate filing, read and explained by AI within minutes — impact, key figures, short/long-term view and what to watch.
Live · AI analyzer runs every 5 min (07:00–23:55 IST)
Latest filing: 2026-08-12 21:38
690 analysed today
690
Today
133,579
All-time analysed
40,122
Positive
6,284
Negative
79,354
Neutral
7,751
Watch
📊 Last 7 days — analysed filings by sentiment
Note: These are AI-generated, educational summaries of public NSE
filings — grounded in each document, but not investment advice and possibly incomplete.
Verify against the original filing and consult a SEBI-registered adviser before acting.
48 announcements match the current filters (relevance ≥ 5).
Apollo Hospitals Targets ₹25,000 Cr HealthCo Revenue Run Rate by Q4 FY27
Apollo Hospitals (AHEL) has provided a strategic update on its HealthCo and Keimed merger, reporting a combined proforma revenue of ₹5,346.8 Cr for Q1 FY27. The company is targeting a massive annualized revenue run rate of ₹25,000 Cr for this integrated entity by Q4 FY27, with expected EBITDA margins of 6.5-7.0%. AHEL expects to list the 'New Co' (HealthCo) by Q4 FY27, maintaining a 59.2% majority stake. Digital 24/7 operating costs for the quarter stood at ₹81.1 Cr as the segment moves toward profitability.
Confidence: HIGH
What changedThe company has formalized the listing timeline for its integrated pharmacy and digital business (HealthCo) for Q4 FY27 and set a clear ₹25,000 Cr revenue run-rate target.
Why it mattersThe consolidation and listing of HealthCo simplify the corporate structure and create a massive integrated healthcare platform, potentially leading to a valuation re-rating of the parent company.
Combined Q1 Revenue: ₹5,346.8 CrTarget Annualized Revenue (Q4 FY27): ₹25,000 CrAHEL Stake in New Co: 59.2%Digital 24/7 Op Cost (Q1): ₹81.1 CrTarget EBITDA Margin: 6.5% - 7.0%
📅 Short termThe market is likely to view the clarity on the listing timeline and aggressive revenue targets for the pharmacy business as a positive development.
📈 Long termThe successful integration of Keimed and the listing of HealthCo represent a structural shift toward a dominant omni-channel healthcare player in India.
⚠ Risk flags
- Regulatory approval delays for the merger
- Execution risk in achieving the ₹25,000 Cr run rate
- Continued cash burn in digital operations
Key Highlights
Combined proforma revenue for HealthCo and Keimed reached ₹5,346.8 Cr in Q1 FY27
Targeting an annualized revenue run rate of ₹25,000 Cr for the integrated entity by Q4 FY27
Estimated listing of the merged 'New Co' scheduled for Q4 FY27 post-regulatory approvals
AHEL to retain a 59.2% stake in the combined entity following the Keimed amalgamation
Digital 24/7 operating costs (excluding ESOP) were ₹81.1 Cr for the June 2026 quarter
👀 What to Watch
Monitor the NCLT and shareholder approval process for the Keimed merger and the specific listing timeline in Q4 FY27, which serves as a major value-unlocking catalyst.
Apollo Hospitals Targets Rs 25,000 Cr HealthCo Revenue Run Rate by Q4 FY27
Apollo Hospitals (AHEL) reported its Q1 FY27 investor update, highlighting a proforma combined revenue of Rs 5,346.8 Cr for its HealthCo and Keimed segments. The company is on track for the composite scheme to merge Keimed into Apollo HealthCo, with an estimated listing of the new entity by Q4 FY27. Management has set a target annualized revenue run rate of Rs 25,000 Cr for the new entity by Q4 FY27, with EBITDA margins expected between 6.5% and 7.0%. The core hospital segment continues its aggressive expansion, targeting 4,300 additional beds across 15 new hospitals.
Confidence: HIGH
What changedThe company provided a concrete timeline for the listing of its pharmacy and digital business (Q4 FY27) and specific financial targets for the merged entity.
Why it mattersThe reorganization simplifies the corporate structure, consolidates the pharmacy supply chain, and provides a clear path to profitability for the digital segment, which has been a drag on margins.
New Co Q1 Revenue: Rs 5,346.8 CrTarget Revenue Run Rate: Rs 25,000 CrAHEL Stake in New Co: 59.2%Planned Bed Addition: 4,300 unitsDigital Platform Users: 44 million
📅 Short termThe stock may see positive sentiment due to the clarity on the HealthCo listing timeline and the narrowing of digital losses.
📈 Long termThe addition of 4,300 beds (approx. 40% increase over current capacity) and the scaling of the omni-channel pharmacy business are structural growth drivers for the next 3-4 years.
⚠ Risk flags
🔬 Flagged for deeper Multibagger analysis — view briefs →
- Execution risk in Keimed merger
- Regulatory pricing pressure on pharmacy margins
- Continued cash burn in digital therapeutics
Key Highlights
Targeting Rs 25,000 Cr annualized revenue run rate for the new HealthCo entity by Q4 FY27
Q1 FY27 combined EBITDA for HealthCo and Keimed reached Rs 389.8 Cr at a 7.3% margin
Apollo 24/7 digital platform operating costs stood at Rs 81.1 Cr for the quarter
Planned expansion of 4,300 beds across 15 new hospitals in Metro Tier 1 and Tier 2 cities
AHEL to retain a 59.2% controlling stake in the new entity post-merger and listing
👀 What to Watch
Investors should monitor the regulatory and NCLT approval progress for the Keimed merger and the subsequent listing of Apollo HealthCo, which is a key value-unlocking event.
Apollo Hospitals Q1 Standalone PAT up 25.5% to ₹385 Cr; FMCG Slump Sale Approved
Apollo Hospitals reported a strong standalone performance for Q1 FY27, with revenue growing 22.5% YoY to ₹2,656.1 Cr. Standalone PAT rose 25.5% to ₹385.2 Cr, driven by a 20.2% increase in EBITDA to ₹656.2 Cr. The board also approved a slump sale of the FMCG and wellness distribution business from its material subsidiary, Apollo Healthco, to a new wholly-owned subsidiary, Apollo Consumer Products Ltd. Additionally, Price Waterhouse was appointed as the statutory auditor for a five-year term starting in 2027.
Confidence: HIGH
What changedApollo reported its Q1 FY27 standalone results and initiated a corporate restructuring to move its FMCG distribution business into a dedicated subsidiary.
Why it mattersThe strong standalone growth reflects robust hospital operations, while the slump sale of the FMCG unit indicates a strategic move to streamline the retail and distribution business structure.
Standalone Revenue (Q1 FY27): ₹2,656.1 CrStandalone PAT (Q1 FY27): ₹385.2 CrStandalone EBITDA: ₹656.2 CrQ1 Standalone Revenue vs TTM Revenue: 10.53%ESOP Grant (Shares): 46,798
📅 Short termThe stock is likely to react positively to the double-digit growth in standalone revenue and profitability.
📈 Long termThe company's focus on high-end surgical cases, pharmacy expansion, and narrowing digital platform losses supports a positive long-term outlook.
⚠ Risk flags
- Regulatory changes in healthcare pricing
- Continued cash burn in the Apollo 24/7 digital platform
Key Highlights
Standalone Revenue from operations increased 22.5% YoY to ₹2,656.1 Cr in Q1 FY27
Standalone Profit After Tax (PAT) grew 25.5% YoY to ₹385.2 Cr from ₹306.9 Cr
Standalone EBITDA reached ₹656.2 Cr, up 20.2% compared to ₹546.1 Cr in Q1 FY26
Approved slump sale of FMCG and wellness undertaking from Apollo Healthco Ltd to Apollo Consumer Products Ltd
Granted 46,798 additional stock options and RSUs to new employees under the 2024 ESOP plan
👀 What to Watch
Investors should monitor the consolidated results to assess the impact of Apollo 24/7's narrowing losses and the execution of the planned 4,300-bed capacity expansion.
25.5% PAT Growth: Apollo Hospitals Reports Q1 FY27 Standalone Revenue of ₹2,656 Cr
Apollo Hospitals reported a strong standalone performance for Q1 FY27, with revenue from operations reaching ₹2,656.1 Cr, a 22.5% increase from ₹2,167.9 Cr in Q1 FY26. Standalone Profit After Tax (PAT) grew 25.5% YoY to ₹385.2 Cr, while EBITDA rose 20.2% to ₹656.2 Cr. The company also announced a strategic slump sale of its FMCG and wellness undertaking from its subsidiary Apollo Healthco to a new wholly-owned subsidiary, Apollo Consumer Products Limited. Additionally, Price Waterhouse was appointed as the statutory auditor for a five-year term starting in 2027.
Confidence: HIGH
What changedApollo Hospitals reported its Q1 FY27 standalone financial results, initiated a corporate restructuring of its FMCG business, and appointed new statutory auditors for a future term.
Why it mattersThe strong standalone growth reflects robust demand in hospital services and improved operational efficiency. The slump sale of the FMCG business suggests a strategic move to streamline consumer-facing operations for better focus or potential monetization.
Standalone Revenue (Q1 FY27): ₹2,656.1 CrStandalone PAT (Q1 FY27): ₹385.2 CrEBITDA (Q1 FY27): ₹656.2 CrYoY Revenue Growth: 22.5%YoY PAT Growth: 25.5%ESOP Grant: 46,798 shares
📅 Short termThe stock may react positively to the double-digit growth in standalone revenue and profitability, which exceeded the previous year's performance.
📈 Long termThe company's focus on high-end surgical mix, bed expansion, and the narrowing losses in the digital segment support a positive structural outlook over the next few years.
⚠ Risk flags
- Regulatory changes in healthcare pricing
- Execution risk of the 4,300-bed expansion
- Continued cash burn in the digital platform (Apollo 24/7)
Key Highlights
Standalone revenue from operations grew 22.5% YoY to ₹2,656.1 Cr in Q1 FY27
Standalone PAT increased to ₹385.2 Cr compared to ₹306.9 Cr in the previous year's corresponding quarter
EBITDA for the quarter stood at ₹656.2 Cr, up from ₹546.1 Cr in Q1 FY26
Board approved the grant of 46,798 additional stock options under the Apollo ESOP Plan 2024
Subsidiary Apollo Healthco to transfer its FMCG/wellness business to Apollo Consumer Products via a slump sale
👀 What to Watch
Investors should monitor the consolidated results to assess the performance of the Apollo 24/7 digital platform and the impact of the FMCG business restructuring. The execution of the planned 4,300-bed expansion remains a key long-term growth driver.
Apollo Hospitals Q1 Standalone PAT Rises 25.5% YoY to ₹385 Cr; Subsidiary Slump Sale Approved
Apollo Hospitals reported a strong standalone performance for Q1 FY27, with revenue growing 22.5% YoY to ₹2,656.1 Cr. Standalone PAT increased 25.5% YoY to ₹385.2 Cr, while EBITDA rose 20.2% to ₹656.2 Cr. The company also announced a structural change where its material subsidiary, Apollo Healthco (AHL), will transfer its FMCG wholesale distribution business to a new wholly-owned subsidiary, ACPL, via a slump sale. Additionally, Price Waterhouse was appointed as the statutory auditor for a five-year term starting from the 2027 AGM.
Confidence: HIGH
What changedApollo Hospitals reported double-digit growth in its standalone Q1 FY27 results and initiated a corporate restructuring of its pharmacy/FMCG distribution business within its subsidiary Apollo Healthco.
Why it mattersThe strong standalone growth confirms the robust demand in core hospital services and improved surgical mix. The slump sale in the subsidiary suggests a strategic move to isolate the FMCG wholesale business, potentially for operational efficiency or future monetization.
Standalone Revenue (Q1 FY27): ₹2,656.1 CrStandalone PAT (Q1 FY27): ₹385.2 CrYoY Revenue Growth: 22.5%YoY PAT Growth: 25.5%EBITDA: ₹656.2 CrESOP Grant (Shares): 46,798 units
📅 Short termThe stock is likely to react positively to the 25%+ growth in standalone PAT and steady EBITDA margins, reflecting strong operational performance in the core hospital segment.
📈 Long termThe company's structural growth is supported by its massive bed expansion plan and the scaling of the Apollo 24/7 platform. The consolidation of pharmacy operations and the entry into electric air ambulances indicate a focus on high-tech healthcare leadership.
⚠ Risk flags
- Continued cash burn in the Apollo 24/7 digital platform
- Regulatory risks regarding healthcare pricing and medicine tariffs
- Dependency on Keimed for pharmacy distribution
Key Highlights
Standalone revenue from operations reached ₹2,656.1 Cr in Q1 FY27, up from ₹2,167.9 Cr in Q1 FY26.
Standalone Profit After Tax (PAT) grew to ₹385.2 Cr, representing a 25.5% increase over the same period last year.
EBITDA for the quarter stood at ₹656.2 Cr, a 20.2% growth compared to ₹546.1 Cr in Q1 FY26.
Apollo Healthco Limited to transfer its FMCG and wellness wholesale distribution undertaking to Apollo Consumer Products Limited (ACPL).
Board approved the grant of 46,798 additional stock options/RSUs to new employees under the ESOP 2024 plan.
👀 What to Watch
Investors should monitor the consolidated results to assess the impact of Apollo 24/7's digital platform losses on overall profitability. The execution of the planned 3,500-4,300 bed expansion and the streamlining of the pharmacy distribution business via the AHL slump sale are key long-term value drivers to watch.
Apollo Hospitals to seek approval for Rs 750 Cr NCD issuance and Rs 10/share final dividend
Apollo Hospitals has issued a notice for its 45th AGM on August 25, 2026, to approve a final dividend of Rs 10 per share, bringing the total FY26 dividend to Rs 20. A key agenda item is the proposal to raise up to Rs 750 crore through Non-Convertible Debentures (NCDs), representing approximately 3% of TTM revenue. The meeting will also vote on the re-appointment of founder Dr. Prathap C Reddy as Executive Chairman for a two-year term and Smt. Rama Bijapurkar as an Independent Director for five years. These resolutions aim to maintain management continuity and provide flexible capital for the group's operations.
Confidence: HIGH
What changedThe company has formalized the agenda for its annual shareholder meeting, including a new debt-raising limit and the final dividend declaration for FY26.
Why it mattersThe Rs 750 crore NCD provides incremental capital for the company's expansion plans (3,500-4,300 beds over 4 years) while maintaining a healthy debt-to-equity ratio of 0.32.
Proposed NCD Issuance: Rs 750 crNCD vs TTM Revenue: ~3.0%Final Dividend: Rs 10 per shareTotal FY26 Dividend: Rs 20 per shareInterim Dividend Payout: Rs 143.78 cr
📅 Short termLikely neutral; the dividend was largely expected and the fundraise is small relative to the company's Rs 1.32 lakh crore market cap.
📈 Long termManagement continuity is critical for the execution of the 4-year bed expansion strategy; the modest debt raise supports growth without over-leveraging.
⚠ Risk flags
- Succession planning for the Executive Chairman
- Execution risk on the 4,300-bed expansion plan
Key Highlights
Proposed issuance of Non-Convertible Debentures (NCDs) up to Rs 750 crore on a private placement basis.
Recommendation of a final dividend of Rs 10 per share (200% of face value), following a Rs 10 interim dividend paid in Feb 2026.
Re-appointment of Dr. Prathap C Reddy as Executive Chairman for a 2-year term from June 25, 2026, to June 24, 2028.
Ratification of the interim dividend payout totaling Rs 143.78 crore (Rs 1,437.85 million).
Re-appointment of Smt. Rama Bijapurkar as Independent Director for a second 5-year term starting November 12, 2026.
👀 What to Watch
Monitor the voting results of the AGM on August 25, 2026, to confirm the approval of the NCD fundraise and leadership re-appointments.
Apollo Hospitals Shareholders Approve Composite Scheme of Arrangement with 90.44% Majority
Apollo Hospitals Enterprise Limited (AHEL) has received approval from its equity shareholders, secured creditors, and unsecured creditors for a composite scheme of arrangement. The scheme involves the integration of Apollo Healthco, Keimed Private Limited, and Apollo Healthtech to streamline the pharmacy and digital health business. The resolution was passed with a significant majority, with 90.44% of total equity votes cast in favor. This restructuring is a critical step in the company's long-term strategy to consolidate its pharmacy distribution and digital health ecosystem.
Key Highlights
Equity shareholders approved the scheme with 11.01 crore votes (90.44%) in favor and 1.16 crore votes (9.56%) against.
Public institutional investors showed 85.69% support for the resolution, while public non-institutional support was higher at 96.96%.
Promoter and promoter group voted 100% in favor of the arrangement with 4.02 crore votes.
The scheme involves a composite arrangement between AHEL, Apollo Healthco, Keimed Private Limited, and Apollo Healthtech.
The meetings were held on June 24, 2026, following directions from the NCLT Chennai Bench.
👀 What to Watch
Investors should view this as a positive milestone toward the successful restructuring of Apollo's pharmacy and digital health business. Continue to monitor for final NCLT sanctions and the subsequent impact on the valuation of the Apollo 24/7 platform.
Apollo Hospitals Shareholders Approve Composite Scheme of Arrangement with 90.44% Majority
Apollo Hospitals Enterprise Limited (AHEL) has received shareholder and creditor approval for its composite scheme of arrangement involving Apollo Healthco, Keimed Private Limited, and Apollo Healthtech. In the court-convened meeting held on June 24, 2026, the resolution was passed with a significant 90.44% majority of the total votes polled. Public institutional shareholders supported the move with an 85.69% 'in favor' vote, while promoters voted 100% in favor. This restructuring is a key step in consolidating the company's pharmacy distribution and digital health platforms.
Key Highlights
Composite scheme of arrangement approved by shareholders, secured creditors, and unsecured creditors with requisite majority.
Total votes polled amounted to 12.17 crore, with 11.01 crore votes (90.44%) cast in favor of the resolution.
Public institutional support was strong at 85.69%, while non-institutional public shareholders voted 96.96% in favor.
The scheme involves the integration of Keimed Private Limited and Apollo Healthco into the resultant entity, Apollo Healthtech.
The voting was conducted via remote e-voting and electronic voting during the meeting held on June 24, 2026.
👀 What to Watch
Investors should view this as a positive milestone in the company's efforts to streamline its health-tech and pharmacy businesses. The focus now shifts to final NCLT approvals and the eventual impact on consolidated margins and valuation.
Apollo Hospitals Concludes NCLT Meetings for Restructuring Scheme with Keimed and Healthco
Apollo Hospitals Enterprise Limited (AHEL) successfully conducted NCLT-mandated meetings on June 24, 2026, to approve a composite scheme of arrangement. The scheme involves the integration of Apollo Healthco, Keimed Private Limited, and Apollo Healthtech Limited to streamline the group's pharmacy distribution and digital health segments. While the secured creditors meeting proceeded smoothly, the unsecured creditors meeting required a 30-minute adjournment to achieve the necessary quorum. This procedural milestone is a critical step toward final regulatory approval for the group's restructuring.
Key Highlights
Meetings held on June 24, 2026, for secured creditors, unsecured creditors, and equity shareholders via video conferencing.
Composite scheme involves Apollo Hospitals (Demerged Co), Apollo Healthco (Transferor 1), Keimed (Transferor 2), and Apollo Healthtech (Resultant Co).
Unsecured creditors meeting was adjourned for 30 minutes from 11:00 a.m. to 11:30 a.m. due to initial lack of quorum.
Remote e-voting was conducted from June 20 to June 23, 2026, with additional voting provided during the meetings.
Final voting results under SEBI Regulation 44(3) are pending and will be submitted separately.
👀 What to Watch
Investors should monitor the upcoming disclosure of voting results to confirm stakeholder approval and track the timeline for final NCLT sanctioning of the scheme.
Apollo Hospitals Holds NCLT-Convened Meetings for Composite Scheme of Arrangement
Apollo Hospitals Enterprise Limited (APOLLOHOSP) conducted NCLT-convened meetings on June 24, 2026, for its secured creditors, unsecured creditors, and equity shareholders. The meetings were held to seek approval for a composite scheme of arrangement involving Apollo Healthco Limited, Keimed Private Limited, and Apollo Healthtech Limited. While the unsecured creditors' meeting required a 30-minute adjournment to meet quorum requirements, all proceedings were successfully concluded via video conferencing. The final voting results, which will determine the progress of this corporate restructuring, are expected to be released separately.
Key Highlights
Meetings held on June 24, 2026, for Secured Creditors (10:00 AM), Unsecured Creditors (11:00 AM), and Equity Shareholders (2:30 PM).
The proposed scheme involves the merger/arrangement of Apollo Healthco, Keimed Private Limited, and Apollo Healthtech with the parent company.
Unsecured Creditors meeting was adjourned for 30 minutes due to initial lack of quorum but reconvened at 11:30 AM per NCLT directions.
Remote e-voting was conducted from June 20 to June 23, 2026, with additional e-voting provided during the meetings.
The scheme is being processed under Sections 230 to 232 of the Companies Act, 2013, following NCLT orders dated March, April, and May 2026.
👀 What to Watch
Investors should watch for the upcoming disclosure of the formal voting results to confirm if the scheme has received the necessary majority approval from all stakeholder classes.
Apollo Hospitals Clarifies Governance for Healthtech Listing; Promoter Rights Lapse Below 10%
Apollo Hospitals has issued clarifications regarding the governance structure of Apollo Healthtech Limited, the entity to be independently listed following a composite scheme of arrangement. The company has established a 10% fall-away threshold for aggregate promoter nomination rights and a 5% threshold for individual promoter entities. Additionally, a tiered board representation system has been introduced, limiting the number of nominee directors based on shareholding percentages. These measures, including a commitment to 50% board independence under an executive chairperson, aim to address stakeholder concerns and improve transparency.
Key Highlights
Promoter and promoter group will waive all director nomination rights if aggregate shareholding falls below 10%.
Individual promoter entities will lose nomination rights if their specific holding falls below 5%.
Tiered nomination rights established: 2 directors for 10-15% stake, up to 5 directors for 35% or more stake.
Commitment to maintain at least 50% independent directors on the board if an executive chairperson is in place.
The scheme involves the arrangement of Apollo Healthco and Keimed Private Limited into Apollo Healthtech for independent listing.
👀 What to Watch
Investors should view these governance clarifications as a positive step toward institutional-grade management for the new entity. Continue to monitor the timeline for the independent listing of Apollo Healthtech as it represents a significant value-unlocking event for AHEL shareholders.
Apollo Hospitals Clarifies Healthtech Scheme: 50% Independent Board & 4x MOIC Upside Target
Apollo Hospitals has provided additional governance and financial clarifications regarding the composite scheme of arrangement involving Apollo Healthco, Keimed, and Apollo Healthtech. The proposed Apollo Healthtech board will consist of 50% independent directors (6 members) and includes a 10% fall-away threshold for promoter and investor nomination rights. A key feature is an investor-funded 'Upside Agreement' that rewards management with up to 9% of the upside if a 4x Multiple of Invested Capital (MOIC) is achieved, ensuring no cash outflow from the company. This restructuring aims to unlock value through the independent listing of Apollo Healthtech as a focused healthcare platform.
Key Highlights
Apollo Healthtech board will feature 50% independent representation with 6 independent directors and a Lead Independent Director.
Investor-funded Upside Agreement provides a maximum 9% reward contingent on achieving a minimum 4x MOIC target.
Promoter and investor board nomination rights will lapse if their respective shareholding falls below a 10% threshold.
Ms. Shobana Kamineni is proposed as Executive Chairperson of the new entity, subject to NCLT and shareholder approvals.
The scheme is designed as a composite unified transaction to integrate Apollo Healthco and Keimed for strategic agility.
👀 What to Watch
Investors should support the scheme as it clarifies governance standards and aligns management incentives with significant value creation targets (4x MOIC) without financial burden to the company. Monitor the upcoming NCLT-convened shareholder meetings for formal approval of the arrangement.
Apollo Hospitals Schedules NCLT-Convened Meeting for Composite Scheme on June 24, 2026
Apollo Hospitals Enterprise Limited has announced an NCLT-convened meeting on June 24, 2026, to seek shareholder approval for a composite scheme of arrangement. The scheme involves the restructuring and integration of Apollo Healthco Limited, Keimed Private Limited, and Apollo Healthtech Limited. Remote e-voting for shareholders will be available from June 20 to June 23, 2026, with a cut-off date of June 17, 2026. The approval requires a three-fourths majority in value of the voting shareholders and a majority of public shareholders to pass.
Key Highlights
NCLT-convened meeting for equity shareholders scheduled for June 24, 2026, at 2:30 PM via VC/OAVM.
Remote e-voting period set from June 20, 2026 (9:00 AM) to June 23, 2026 (5:00 PM).
Cut-off date for determining voting eligibility is June 17, 2026.
Quorum for the equity shareholders' meeting is fixed at 35,640 members.
Scheme requires approval from 75% in value of voting shareholders and a majority of public shareholders.
👀 What to Watch
Investors should review the scheme of arrangement details to understand the impact of the Keimed and Healthco integration on the company's valuation. Shareholders are advised to cast their votes during the e-voting window ending June 23.
Apollo Hospitals Schedules NCLT-Convened Meetings for Composite Scheme on June 24, 2026
Apollo Hospitals Enterprise Limited (AHEL) has announced NCLT-convened meetings for equity shareholders and creditors on June 24, 2026, to approve a composite scheme of arrangement. The scheme involves the restructuring of Apollo Healthco, Keimed Private Limited, and Apollo Healthtech. For the scheme to proceed, it requires approval from a majority of shareholders representing three-fourths in value of those voting. Additionally, the scheme is conditional upon the votes cast by public shareholders in favor exceeding those cast against it.
Key Highlights
NCLT-convened meetings for equity shareholders scheduled for June 24, 2026, at 2:30 PM via VC/OAVM.
Composite scheme involves Apollo Hospitals, Apollo Healthco, Keimed Private Limited, and Apollo Healthtech.
Approval requires a 75% majority in value of the equity shareholders present and voting.
Cut-off date for determining voting eligibility is June 17, 2026, with remote e-voting from June 20 to June 23.
Quorum for the equity shareholders' meeting is specifically set at 35,640 members.
👀 What to Watch
Investors should evaluate the long-term impact of integrating Keimed and the pharmacy business restructuring on AHEL's margins. Monitor the voting results expected within two working days of the June 24 meeting for confirmation of shareholder support.
Apollo Hospitals Sets June 24 Shareholder Meeting for Major Restructuring and Merger Scheme
Apollo Hospitals (AHEL) has scheduled an NCLT-convened meeting for equity shareholders on June 24, 2026, to vote on a composite scheme of arrangement. The scheme involves the restructuring of Apollo Healthco, the merger of Keimed Private Limited, and the involvement of Apollo Healthtech. This consolidation aims to streamline the company's pharmacy distribution and digital health platforms. Shareholders as of the cut-off date of June 17, 2026, are eligible to participate in the voting process via remote e-voting starting June 20, 2026.
Key Highlights
NCLT-convened meeting of equity shareholders scheduled for June 24, 2026, via Video Conferencing.
Cut-off date for determining voting eligibility is June 17, 2026.
Remote e-voting period is set from June 20, 2026 (9:00 AM) to June 23, 2026 (5:00 PM).
The scheme involves a composite arrangement between AHEL, Apollo Healthco, Keimed Private Ltd, and Apollo Healthtech.
Valuation reports and fairness opinions were finalized in June 2025 by KPMG, BDO, and Axis Capital.
👀 What to Watch
Investors should review the specific share entitlement ratios provided in the valuation reports to understand the dilutive or accretive impact of the Keimed merger. This is a critical structural change for Apollo's digital and pharmacy ecosystem and requires a vote by June 24.
Apollo Hospitals Schedules June 24 Shareholder Meeting for Major Composite Scheme of Arrangement
Apollo Hospitals Enterprise Limited (AHEL) has announced an NCLT-convened meeting of equity shareholders on June 24, 2026, to approve a composite scheme of arrangement. The scheme involves the restructuring of Apollo Healthco, Keimed Private Limited, and Apollo Healthtech to consolidate the group's pharmacy distribution and digital health business (Apollo 24/7). Shareholders as of the June 17, 2026, cut-off date are eligible to vote on this proposal, which is a critical step toward final legal approval for the restructuring. This move is expected to streamline operations and potentially unlock value in the high-growth digital health segment.
Key Highlights
NCLT-convened meeting of equity shareholders scheduled for June 24, 2026, via Video Conferencing.
Scheme involves the merger of Keimed Private Limited and Apollo Healthco into Apollo Healthtech Limited.
Remote e-voting period is set from June 20, 2026 (9:00 AM) to June 23, 2026 (5:00 PM).
Joint valuation report provided by KPMG and BDO with a fairness opinion from Axis Capital Limited.
The cut-off date for determining shareholder voting eligibility is June 17, 2026.
👀 What to Watch
Investors should review the scheme details and participate in the voting process as this restructuring significantly impacts the company's digital and pharmacy asset valuation.
Apollo Hospitals Schedules Shareholder Meeting on June 24 for Composite Scheme of Arrangement
Apollo Hospitals (AHEL) has announced an NCLT-convened meeting of equity shareholders on June 24, 2026, to approve a major composite scheme of arrangement. The scheme involves the demerger of an identified business undertaking and the merger of Apollo Healthco and Keimed Private Limited into Apollo Healthtech Limited. This restructuring is a strategic move to consolidate the pharmacy distribution and digital health business (Apollo 24/7) under a streamlined structure. Shareholders as of the June 17, 2026, cut-off date are eligible to vote on the proposal.
Key Highlights
NCLT-convened meeting scheduled for June 24, 2026, at 2:30 PM via Video Conferencing.
Scheme involves Apollo Hospitals, Apollo Healthco, Keimed Private Limited, and Apollo Healthtech.
Remote e-voting period starts on June 20, 2026, and ends on June 23, 2026.
The arrangement follows regulatory approvals including the CCI order and observation letters from BSE and NSE issued in December 2025.
The restructuring aims to integrate the pharmacy supply chain and digital health platform to unlock value.
👀 What to Watch
Investors should review the share entitlement ratios provided in the valuation reports to understand the impact on their holdings. The consolidation of Keimed is expected to be margin-accretive for the pharmacy business, making this a key development to support.
Apollo Hospitals Sets June 24, 2026 Meeting for Major Composite Scheme of Arrangement
Apollo Hospitals (AHEL) has scheduled a court-convened shareholder meeting on June 24, 2026, to seek approval for a significant composite scheme of arrangement. The restructuring involves Apollo Healthco Limited, Keimed Private Limited, and Apollo Healthtech Limited, aiming to consolidate the pharmacy distribution and digital health ecosystem. Shareholders as of the June 17, 2026, cut-off date are eligible to vote on the proposal, which has already received necessary observations from BSE and NSE and approval from the CCI. This move is a critical step in the company's long-term strategy to streamline its health-tech and supply chain operations.
Key Highlights
Court-convened meeting scheduled for June 24, 2026, via Video Conferencing per NCLT Chennai orders.
Scheme involves the integration of Apollo Healthco, Keimed Private Limited, and Apollo Healthtech Limited.
Voting eligibility is determined by a cut-off date of June 17, 2026, with remote e-voting from June 20-23.
The arrangement includes a joint valuation report from KPMG and BDO and a fairness opinion from Axis Capital.
The restructuring follows regulatory clearances including a CCI order and stock exchange observation letters from December 2025.
👀 What to Watch
Investors should support the restructuring as it consolidates the pharmacy supply chain and digital assets, which is expected to improve operational efficiency. Review the specific share entitlement ratios in the valuation reports to understand the impact on individual holdings.
Apollo Hospitals Merges Cradle & Fertility Units with Cloudnine in INR 1,550 Cr Deal
Apollo Health and Lifestyle Limited (AHLL), a subsidiary of Apollo Hospitals, is merging its 'Apollo Cradle' and 'Apollo Fertility' businesses with 'Cloudnine' to create a dominant maternity and fertility platform. The transaction values AHLL's specific verticals at INR 1,550 Crores, which will be realized through a combination of cash and a 9.9% equity stake in the merged entity. This strategic move makes AHLL the largest non-financial shareholder in the combined platform, which will operate over 55 centers across India. The deal is backed by marquee investors including Temasek and TPG, aiming to synergize operations and expand into Tier 1 and 2 markets.
Key Highlights
AHLL's Mother & Child and Fertility verticals valued at INR 1,550 Crores in the combination deal.
Apollo Health and Lifestyle to hold a 9.9% equity stake and a board seat in the combined entity.
The combined platform will operate 55+ centers, creating one of India's largest integrated maternity networks.
Transaction involves a cash component and is subject to regulatory approvals including the CCI.
👀 What to Watch
Investors should view this as a significant value-unlocking event for Apollo's retail healthcare segment. Monitor the completion of regulatory approvals and the potential for improved margins through this consolidated platform.
Apollo Hospitals FY26 PAT up 15% to ₹1,493 Cr; Divests Units for ₹1,550 Cr
Apollo Hospitals reported a strong performance for FY26, with standalone revenue growing 13.7% to ₹9,326.2 crore and PAT increasing 15% to ₹1,492.6 crore. The company announced a major divestment of its specialty and fertility units to Kids Clinic India (Cloudnine) for an enterprise value of ₹1,550 crore, receiving ₹765 crore in cash and a 9.9% equity stake. A final dividend of ₹10 per share (200%) was recommended, and the board approved the merger of Apollo Hospitals North Ltd into the parent company.
Key Highlights
Standalone Revenue for FY26 rose to ₹9,326.2 crore compared to ₹8,202.1 crore in FY25
Net Profit (PAT) grew 15% YoY to ₹1,492.6 crore with an EPS of ₹103.81
Divesting ASHPL and AFCPL to Cloudnine for ₹1,550 crore, retaining a 9.9% equity stake in the buyer
Recommended a final dividend of ₹10 per equity share (200%) with a record date of August 14, 2026
Re-appointed Dr. Prathap C Reddy as Executive Chairman for a further period of two years
👀 What to Watch
The strong earnings growth and strategic divestment to unlock value in the mother-and-child segment are positive catalysts. Investors should monitor the completion of the Cloudnine transaction and the subsequent impact on consolidated margins.
